Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 197

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

Open access
Dardaei, Leila, Wang, Hui Qin, Singh, Manrose, Fordjour, Paul, Shaw, Katherine X, Yoda, Satoshi, Kerr, Grainne, Yu, Kristine, Liang, Jinsheng, Cao, Yichen, Chen, Yan, Lawrence, Michael S, Langenbucher, Adam, Gainor, Justin F, Friboulet, Luc, Dagogo-Jack, Ibiayi, Myers, David T, Labrot, Emma, Ruddy, David, Parks, Melissa, Lee, Dana, DiCecca, Richard H, Moody, Susan, Hao, Huaixiang, Mohseni, Morvarid, LaMarche, Matthew, Williams, Juliet, Hoffmaster, Keith, Caponigro, Giordano, Shaw, Alice T, Hata, Aaron N, Benes, Cyril H, Li, Fang, Engelman, Jeffrey A · 2018 · Nature Medicine

Abstract

Most anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung tumors initially respond to small-molecule ALK inhibitors, but drug resistance often develops. Of tumors that develop resistance to highly potent second-generation ALK inhibitors, approximately half harbor resistance mutations in ALK, while the other half have other mechanisms underlying resistance. Members of the latter group often have activation of at least one of several different tyrosine kinases driving resistance. Such tumors are not expected to respond to lorlatinib—a third-generation inhibitor targeting ALK that is able to overcome all clinically identified resistant mutations in ALK—and further therapeutic options are limited. Herein, we deployed a shRNA screen of 1,000 genes in multiple ALK-inhibitor-resistant patient-derived cells (PDCs) to discover those that confer sensitivity to ALK inhibition. This approach identified SHP2, a nonreceptor protein tyrosine phosphatase, as a common targetable resistance node in multiple PDCs. SHP2 provides a parallel survival input downstream of multiple tyrosine kinases that promote resistance to ALK inhibitors. Treatment with SHP099, the recently discovered small-molecule inhibitor of SHP2, in combination with the ALK tyrosine kinase inhibitor (TKI) ceritinib halted the growth of resistant PDCs through preventing compensatory RAS and ERK1 and ERK2 (ERK1/2) reactivation. These findings suggest that combined ALK and SHP2 inhibition may be a promising therapeutic strategy for resistant cancers driven by several different ALK-independent mechanisms underlying resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.4497

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

Metadata

Authors
Dardaei, L., Wang, H. Q., Singh, M., Fordjour, P., Shaw, K. X., Yoda, S., Kerr, G., Yu, K., Liang, J., Cao, Y., Chen, Y., Lawrence, M. S., Langenbucher, A., Gainor, J. F., Friboulet, L., Dagogo-Jack, I., Myers, D. T., Labrot, E., Ruddy, D., Parks, M., Lee, D., DiCecca, R. H., Moody, S., Hao, H., Mohseni, M., LaMarche, M., Williams, J., Hoffmaster, K., Caponigro, G., Shaw, A. T., Hata, A. N., Benes, C. H., Li, F., & Engelman, J. A.
Venue
Nature Medicine
Published
2018-03-05
Volume
24
Issue
4
Pages
512-517
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2789632821
Cited by
197
References
9
FWCI
18.94
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.